SD
SDZXF.US Sandoz Group AG
- Market cap
- USD 42.6B
- P/E
- 67.0x
- P/B
- 4.73x
- ROE
- 9.7%
- Dividend yield
- 0.74%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is SDZXF.US undervalued?
Graham numberThe Graham number of Sandoz Group AG cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sandoz Group AG fundamental analysis
No fundamental analysis for Sandoz Group AG yet.
Sandoz Group AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a str…
Full company profileSandoz Group AG financial statements
Sandoz Group AG annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | - | 9.31B | 9.98B | 10.4B | 11.2B |
| Gross Profit | - | - | 4.38B | 4.56B | 4.93B | 5.28B |
| Operating Income | - | - | -22.5K | 375M | 307M | 1.43B |
| EBITDA | - | - | 1.68B | 857M | 742M | 1.97B |
| Net Income | - | - | -22.9K | 77.0M | 0.00 | 914M |
| EPS | - | - | 0.00 | 0.18 | 0.00 | 2.11 |
| Balance Sheet | ||||||
| Total Assets | - | - | 100K | 19.4B | 19.9B | 22.0B |
| Total Liabilities | - | - | 22.9K | 10.8B | 11.7B | 12.6B |
| Shareholders' Equity | - | - | 77.1K | 8.65B | 8.16B | 9.39B |
| Cash & Short-term Investments | - | - | 100K | 1.11B | 1.19B | 1.74B |
| Cash Flow | ||||||
| Operating Cash Flow | 1.10B | 1.35B | 1.22B | 362M | 656M | 1.59B |
| Capital Expenditure | 226M | 313M | 278M | 625M | 596M | 784M |
| Free Cash Flow | - | - | 796M | -263M | 60.0M | 810M |
| Ratios | ||||||
| ROE | - | - | -29.6% | 0.9% | 0.0% | 9.7% |
| ROA | - | - | -22.9% | 0.4% | 0.0% | 4.1% |
| Net Profit Margin | - | - | 0.0% | 0.8% | 0.0% | 8.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sandoz Group AG dividends
- Dividend yield
- 0.74%
- Forward dividend
- 1.02 USD
- Payout ratio
- 34.5%
- Ex-dividend date
- Apr 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 315M | 0.73 | 34.5% |
| 2024 | USD 215M | 0.50 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sandoz Group AG
- Insiders 4.19%
- Institutions 55.74%
- Public & others 40.07%
- Shares outstanding 433M
- Free float 435M
Sandoz Group AG company profile
- Company name
- Sandoz Group AG
- Ticker
- SDZXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 20,000
- Fiscal year end
- December
- Address
- Centralbahnstrasse 4, Basel, Switzerland, 4051
- Phone
- 41 61 324 11 11
- Website
- sandoz.com
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Sandoz Group AG management
10- Mr. Richard SaynorChief Executive Officer · born 1967
- Mr. Remco J. SteenbergenChief Financial Officer · born 1968
- Mr. Asaf GalChief Technology Officer · born 1969
- Ms. Claire D'Abreu-HaylingChief Scientific Officer & President of Generics Development · born 1964
- Mr. Craig MarksHead of Investor Relations
- Ms. Ingrid SollererGeneral Counsel & Chief Compliance Officer · born 1974
- Ms. Tripti JhaChief People Officer · born 1977
- Dr. Glenn A. Gerecke Ph.D.Chief Manufacturing & Supply Officer · born 1959
- Ms. Rebecca GunternChief Commercial Officer · born 1972
- Ms. Keren HaruviPresident of North America · born 1980